Compare · AMIX vs BSX
AMIX vs BSX
Side-by-side comparison of Autonomix Medical Inc. (AMIX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMIX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 10349.6x AMIX ($7.0M).
- Over the past year, AMIX is down 70.3% and BSX is down 53.1% - BSX leads by 17.2 points.
- BSX has been more active in the news (10 items in the past 4 weeks vs 6 for AMIX).
- BSX has more recent analyst coverage (25 ratings vs 0 for AMIX).
- Company
- Autonomix Medical Inc.
- Boston Scientific Corporation
- Price
- -
- -
- Market cap
- $7.0M
- $72.26B
- 1M return
- +141.40%
- +9.58%
- 1Y return
- -70.32%
- -53.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 6
- 10
- Recent ratings
- 0
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest AMIX
- Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
- SEC Form 10-Q filed by Autonomix Medical Inc.
- Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
- Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
- SEC Form EFFECT filed by Autonomix Medical Inc.
- Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
- SEC Form 424B5 filed by Autonomix Medical Inc.
- SEC Form S-3 filed by Autonomix Medical Inc.
- Autonomix Medical Inc. filed SEC Form 8-K: Other Events
- Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation